➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Express Scripts
Harvard Business School
McKinsey
Mallinckrodt

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,092,542

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,092,542
Title:Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione
Abstract: Stereomerically pure (+)-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoiso- indoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoin- doline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-.alpha. or the inhibition of PDE4.
Inventor(s): Muller; George W. (Rancho Santa Fe, CA), Schafer; Peter H. (Belle Mead, NJ), Man; Hon-Wah (Princeton, NJ), Ge; Chuansheng (Belle Mead, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:15/629,678
Patent Claims:1. A method of treating or managing bone loss, which comprises administering to a patient a therapeutically effective amount of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-4-acetylamino- isoindolin-1,3-dione: ##STR00002## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the bone loss is a primary bone loss.

3. The method of claim 2, wherein the primary bone loss is primary type 1 osteoporosis.

4. The method of claim 2, wherein the primary bone loss is primary type 2 osteoporosis.

5. The method of claim 1, wherein the bone loss is secondary to other underlying disorders.

6. The method of claim 5, wherein the underlying disorder is: rheumatoid arthritis; lupus; multiple sclerosis; ankylosing spondylitis; a digestive or gastrointestinal disorder; a digestive or gastrointestinal disorder; a hematologic disorder; stroke; Parkinson's disease; multiple sclerosis; spinal cord injury; a mental illness; bone cancer; breast cancer; or prostate cancer.

7. The method of claim 6, wherein the digestive or gastrointestinal disorder is celiac disease or inflammatory bowel disease.

8. The method of claim 6, wherein the digestive or gastrointestinal disorder is diabetes, hyperparathyroidism, hyperthyroidism, Cushing's syndrome, thyrotoxicosis, premature menopause, or unusual testosterone levels.

9. The method claim 6, wherein the hematologic disorder is leukemia, lymphoma, multiple myeloma, sickle cell disease, a blood and bone marrow disorder or thalassemia.

10. The method of claim 6, wherein the mental illness is depression or an eating disorder.

11. The method of claim 1, wherein the bone loss is caused by a therapeutic agent.

12. The method of claim 11, wherein the therapeutic agent is a corticosteroid, an antiepileptic, L-thyroxine, an aromatase inhibitor, methotrexate, depot-progesterone, a gonadotropin-releasing hormone agonist, a proton pump inhibitor, a thiazolidinedione, or lithium.

13. The method of claim 12, wherein the corticosteroid is prednisone or dexamethasone.

14. The method of claim 12, wherein the antiepileptic is a barbiturate or phenytoin.

15. The method of claim 1, wherein the bone loss is osteogenesis imperfecta, osteomalacia, rickets, ostesis fibrosa cystic or Paget's disease.

16. The method of claim 1, wherein the (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-4-acetylamino- isoindolin-1,3-dione or a pharmaceutically acceptable salt, is administered in combination or alternation with a therapeutically effective amount of one or more additional active agents.

17. The method of claim 16, wherein the additional agent is a bisphosphonate, teriparatide, strontium renelate, raloxifene, denosumab, calcium, vitamin D, vitamin K or a combination thereof.

Details for Patent 10,092,542

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial Celgene Corporation (Summit, NJ) 2022-03-20 RX Orphan search
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01   Start Trial Celgene Corporation (Summit, NJ) 2022-03-20 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
Dow
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.